Sanofi-Aventis Outpaces Other International Drug Players In High-speed Growth In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Boosted by China's ever-expanding economy and ongoing health reforms, part of which are aimed at covering 90 percent of the country's 1.3 billion citizens with minimal medical insurance by 2011, drug firms posted an average sales growth rate of 27 percent in 2009, according to the global information provider IMS Health
You may also be interested in...
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts